Canada’s Valeant Pharmaceuticals divides opinion in the investment world. To some it’s the whip-smart upstart feasting on the bloated and bumbling big pharma sector, while to others it’s a rapacious predator, or even a roll-up vehicle that will eventually crash to Earth. But what’s staid and sensible AstraZeneca (LSE: AZN) doing making deals with it?
Youâre reading a free article with opinions that may differ from The Motley Foolâs Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.
RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partnerâs brokerage products, these are focused on the trading of readily releasable securities.
AstraZeneca plc In New Partnership With Controversial Valeant Pharmaceuticals Intl Inc
VIDEO: One Fool takes a closer look at AstraZeneca plc (LON:AZN) and Valeant Pharmaceuticals Intl Inc (NYSE:VRX).
Posted by
Published
More on: AZN
The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.
Youâre reading a free article with opinions that may differ from The Motley Foolâs Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.
RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partnerâs brokerage products, these are focused on the trading of readily releasable securities.
